A citation-based method for searching scientific literature

A J Palmer, R Chen, W J Valentine, S Roze, B Bregman, N Mehin, S Gabriel. Diabetes Metab 2006
Times Cited: 10







List of co-cited articles
83 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
H H Parving, H Lehnert, J Bröchner-Mortensen, R Gomis, S Andersen, P Arner. N Engl J Med 2001
50

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
E J Lewis, L G Hunsicker, W R Clarke, T Berl, M A Pohl, J B Lewis, E Ritz, R C Atkins, R Rohde, I Raz. N Engl J Med 2001
50

The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy.
Roger A Rodby, Chion Fang Chiou, Jeff Borenstein, Allison Smitten, Nishan Sengupta, Andrew J Palmer, Stéphane Roze, Lieven Annemans, Teresa A Simon, Roland S Chen,[...]. Clin Ther 2003
41
50


Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
B M Brenner, M E Cooper, D de Zeeuw, W F Keane, W E Mitch, H H Parving, G Remuzzi, S M Snapinn, Z Zhang, S Shahinfar. N Engl J Med 2001
40

A computer simulation model of diabetes progression, quality of life, and cost.
Honghong Zhou, Deanna J M Isaman, Shari Messinger, Morton B Brown, Ronald Klein, Michael Brandle, William H Herman. Diabetes Care 2005
79
30


2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).
Giuseppe Mancia, Guy De Backer, Anna Dominiczak, Renata Cifkova, Robert Fagard, Giuseppe Germano, Guido Grassi, Anthony M Heagerty, Sverre E Kjeldsen, Stephane Laurent,[...]. J Hypertens 2007
30

Global burden of hypertension: analysis of worldwide data.
Patricia M Kearney, Megan Whelton, Kristi Reynolds, Paul Muntner, Paul K Whelton, Jiang He. Lancet 2005
30


Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria.
Andrew J Palmer, Lieven Annemans, Stéphane Roze, Pablo Lapuerta, Roland Chen, Sylvie Gabriel, Paulo Carita, Roger A Rodby, Dick de Zeeuw, Hans-Henrik Parving,[...]. Kidney Int Suppl 2005
16
30

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Björn Dahlöf, Richard B Devereux, Sverre E Kjeldsen, Stevo Julius, Gareth Beevers, Ulf de Faire, Frej Fyhrquist, Hans Ibsen, Krister Kristiansson, Ole Lederballe-Pedersen,[...]. Lancet 2002
30

A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.
Andrew J Palmer, William J Valentine, Daniel M D Tucker, Joshua A Ray, Stéphane Roze, Lieven Annemans, Pablo Lapuerta, Roland Chen, Sylvie Gabriel, Paulo Carita,[...]. Curr Med Res Opin 2006
7
42

An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting.
A J Palmer, L Annemans, S Roze, M Lamotte, R A Rodby, R W Bilous. J Hum Hypertens 2004
26
30



Diabetes nephropathy in the Netherlands: a cost effectiveness analysis of national clinical guidelines.
N van Os, L W Niessen, H J Bilo, A F Casparie, B A van Hout. Health Policy 2000
22
30


A health policy model of CKD: 1. Model construction, assumptions, and validation of health consequences.
Thomas J Hoerger, John S Wittenborn, Joel E Segel, Nilka R Burrows, Kumiko Imai, Paul Eggers, Meda E Pavkov, Regina Jordan, Susan M Hailpern, Anton C Schoolwerth,[...]. Am J Kidney Dis 2010
65
30

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
Christoph Wanner, Vera Krane, Winfried März, Manfred Olschewski, Johannes F E Mann, Günther Ruf, Eberhard Ritz. N Engl J Med 2005
20


Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74.
Ravi Retnakaran, Carole A Cull, Kerensa I Thorne, Amanda I Adler, Rury R Holman. Diabetes 2006
589
20

Arterial hypertension, microalbuminuria, and risk of ischemic heart disease.
J S Jensen, B Feldt-Rasmussen, S Strandgaard, M Schroll, K Borch-Johnsen. Hypertension 2000
315
20

Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.
H C Gerstein, J F Mann, Q Yi, B Zinman, S F Dinneen, B Hoogwerf, J P Hallé, J Young, A Rashkow, C Joyce,[...]. JAMA 2001
20

Economic burden of cardiovascular diseases in the enlarged European Union.
José Leal, Ramón Luengo-Fernández, Alastair Gray, Sophie Petersen, Mike Rayner. Eur Heart J 2006
414
20



Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.
Stevo Julius, Sverre E Kjeldsen, Michael Weber, Hans R Brunner, Steffan Ekman, Lennart Hansson, Tsushung Hua, John Laragh, Gordon T McInnes, Lada Mitchell,[...]. Lancet 2004
20


Low-grade albuminuria and cardiovascular risk : what is the evidence?
Roland E Schmieder, Joachim Schrader, Walter Zidek, Ulrich Tebbe, W Dieter Paar, Peter Bramlage, D Pittrow, Michael Böhm. Clin Res Cardiol 2007
88
20

Prevention and treatment of diabetic nephropathy: the program for irbesartan mortality and morbidity evaluation.
Maura Ravera, Elena Ratto, Simone Vettoretti, Denise Parodi, Giacomo Deferrari. J Am Soc Nephrol 2005
22
20

Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy.
Frederik Persson, Peter Rossing, Peter Hovind, Coen D A Stehouwer, Casper Schalkwijk, Lise Tarnow, Hans-Henrik Parving. Diabetes 2006
55
20

Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.
Katherine F Croom, Monique P Curran, Karen L Goa, Caroline M Perry. Drugs 2004
55
20

Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations.
Marc A Pohl, Samuel Blumenthal, Daniel J Cordonnier, Fernando De Alvaro, Giacomo Deferrari, Gilbert Eisner, Enric Esmatjes, Richard E Gilbert, Lawrence G Hunsicker, Jose B Lopes de Faria,[...]. J Am Soc Nephrol 2005
240
20

Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
Aram V Chobanian, George L Bakris, Henry R Black, William C Cushman, Lee A Green, Joseph L Izzo, Daniel W Jones, Barry J Materson, Suzanne Oparil, Jackson T Wright,[...]. Hypertension 2003
20

Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland.
Andrew J Palmer, Stéphane Roze, William J Valentine, Joshua A Ray, Andreas Frei, Michel Burnier, Bernhard Hess, Giatgen A Spinas, Michael Brändle. Swiss Med Wkly 2006
5
40

Cost-effectiveness of irbesartan in diabetic nephropathy: a systematic review of published studies.
Andrew J Palmer, Daniel M D Tucker, William J Valentine, Stéphane Roze, Sylvie Gabriel, Daniel J Cordonnier. Nephrol Dial Transplant 2005
16
20

Pharmacoeconomics of angiotensin II antagonists in type 2 diabetic patients with nephropathy: implications for decision making.
Cornelis Boersma, Jarir Atthobari, Ron T Gansevoort, Lolkje T W de Jong-Van den Berg, Paul E de Jong, Dick de Zeeuw, Lieven J P Annemans, Maarten J Postma. Pharmacoeconomics 2006
14
20

Preventing microalbuminuria in type 2 diabetes.
Piero Ruggenenti, Anna Fassi, Anelja Parvanova Ilieva, Simona Bruno, Ilian Petrov Iliev, Varusca Brusegan, Nadia Rubis, Giulia Gherardi, Federica Arnoldi, Maria Ganeva,[...]. N Engl J Med 2004
684
20

Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation.
William H Herman, Shahnaz Shahinfar, George W Carides, Erik J Dasbach, William C Gerth, Charles M Alexander, John R Cook, William F Keane, Barry M Brenner. Diabetes Care 2003
56
20

Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy.
Robert C Atkins, Esther M Briganti, Julia B Lewis, Lawrence G Hunsicker, Gregory Braden, Paul J Champion de Crespigny, Giacomo DeFerrari, Paul Drury, Francesco Locatelli, Thomas B Wiegmann,[...]. Am J Kidney Dis 2005
250
20

Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union.
William C Gerth, Giuseppi Remuzzi, GianCarlo Viberti, Thierry Hannedouche, Alberto Martinez-Castelao, Shahnaz Shahinfar, George W Carides, Barry Brenner. Kidney Int Suppl 2002
16
20

Prevalence of chronic kidney disease in the United States.
Josef Coresh, Elizabeth Selvin, Lesley A Stevens, Jane Manzi, John W Kusek, Paul Eggers, Frederick Van Lente, Andrew S Levey. JAMA 2007
20


Effect of a multifactorial intervention on mortality in type 2 diabetes.
Peter Gaede, Henrik Lund-Andersen, Hans-Henrik Parving, Oluf Pedersen. N Engl J Med 2008
20



ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends.
Aileen Grassmann, Simona Gioberge, Stefan Moeller, Gail Brown. Nephrol Dial Transplant 2005
342
20


Cost-effectiveness of pharmacogenetic testing to predict treatment response to angiotensin-converting enzyme inhibitor.
Madlaina Costa-Scharplatz, Antoinette D I van Asselt, Lucas M Bachmann, Alfons G H Kessels, Johan L Severens. Pharmacogenet Genomics 2007
18
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.